The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer
Open accessAbstract
Aims: To investigate the association between tumour characteristics and HER-2/neu by immunohistochemistry in primary operable breast cancer. Methods: The association between HER-2/neu and other clinicopathological factors was evaluated in 1362 consecutive patients with primary breast cancer treated between 2000 and July 2003 in one centre. Microscopic tumour size, tumour grade, lymph node status, patient’s age, oestrogen receptor (ER), progesterone receptor (PR), and joint ER/PR status were evaluated, using the χ 2 test for univariate analysis and logistic regression for multivariate analysis. The hormone receptors and HER-2/neu were studied immunohistochemically. Using the HER-2/neu DAKO scoring system, scores of 0, 1+, or 2+ were defined as negative and 3+ as positive. Data for DAKO scores 2+/3+ versus 0/1+ are also presented. Results: Hormone receptor negative breast cancers were more often HER-2/neu positive than hormone receptor positive cancers, both for ER (28.7% v 6.8%) and PR (19.9% v 5.9%). In multivariate analysis, both ER, PR, and tumour grade were independently associated with HER-2/neu. In ER + tumours, HER-2/neu overexpression was significantly lower in PR + than in PR − cases (11.5% v 5.4%). HER-2/neu overexpression (2.7%) was lowest in the large subgroup of ER + PR + tumours with low tumour grade (grade 1–2), comprising 46.1% of all patients. Conclusions: ER, PR, and tumour grade are independent predictors for HER-2/neu overexpression in women with primary operable breast cancer. ER and PR are negatively associated with HER-2/neu, whereas tumour grade is positively associated with HER-2/neu. In women with ER + tumours, PR status also affects the likelihood of HER-2/neu expression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Cited by
Ross, J. S., Slodkowska, E. A., Symmans, W. F., Pusztai, L., Ravdin, P. M., & Hortobagyi, G. N. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0230 · Cited by 1,144
Breast Cancer: Epidemiology and Etiology
Tao, Z., Shi, A., Lu, C., Song, T., Zhang, Z., & Zhao, J. (2015) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-014-0459-6 · Cited by 699
Arpino, G., Weiss, H., Lee, A. V., Schiff, R., De Placido, S., Osborne, C. K., & Elledge, R. M. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji249 · Cited by 484
Metadata
- Authors
- Huang, H. J., Neven, P., Drijkoningen, M., Paridaens, R., Wildiers, H., Van Limbergen, E., Berteloot, P., Amant, F., Vergote, I., & Christiaens, M. R.
- Venue
- Journal of Clinical Pathology
- Publisher
- BMJ
- Published
- 2005-05-25
- Volume
- 58
- Issue
- 6
- Pages
- 611-616
- ISSN
- 0021-9746 (ISSN-L)
- 1472-4146
- OpenAlex
- W2073392370
- Cited by
- 175
- References
- 2
- FWCI
- 4.95
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer. https://app.cochat.ai/papers/10.1136/jcp.2004.022772
- The paper
- Huang, H. J., Neven, P., Drijkoningen, M., Paridaens, R., Wildiers, H., Van Limbergen, E., Berteloot, P., Amant, F., Vergote, I., & Christiaens, M. R. (2005). Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer. Journal of Clinical Pathology. https://doi.org/10.1136/jcp.2004.022772
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.